241 related articles for article (PubMed ID: 31882437)
21. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.
Chou ST; Alsawas M; Fasano RM; Field JJ; Hendrickson JE; Howard J; Kameka M; Kwiatkowski JL; Pirenne F; Shi PA; Stowell SR; Thein SL; Westhoff CM; Wong TE; Akl EA
Blood Adv; 2020 Jan; 4(2):327-355. PubMed ID: 31985807
[TBL] [Abstract][Full Text] [Related]
22. Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload.
Koehl B; Missud F; Holvoet L; Ithier G; Sakalian-Black O; Haouari Z; Lesprit E; Baruchel A; Benkerrou M
J Vis Exp; 2017 Mar; (121):. PubMed ID: 28362411
[TBL] [Abstract][Full Text] [Related]
23. Partial manual exchange reduces iron accumulation during chronic red cell transfusions for sickle cell disease.
Savage WJ; Reddoch S; Wolfe J; Casella JF
J Pediatr Hematol Oncol; 2013 Aug; 35(6):434-6. PubMed ID: 23887022
[TBL] [Abstract][Full Text] [Related]
24. Transfusion support for haemoglobinopathies.
Greenwalt TJ; Zelenski KR
Clin Haematol; 1984 Feb; 13(1):151-65. PubMed ID: 6373080
[TBL] [Abstract][Full Text] [Related]
25. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease.
Ballas SK
Semin Hematol; 2001 Jan; 38(1 Suppl 1):30-6. PubMed ID: 11206959
[TBL] [Abstract][Full Text] [Related]
26. Euvolemic automated transfusion to treat severe anemia in sickle cell disease patients at risk of circulatory overload.
Mercure-Corriveau N; Crowe EP; Vozniak S; Feng X; Rai H; Van Denakker T; Zakieh A; Grabowski MK; Lanzkron S; Tobian AAR; Bloch EM
Transfusion; 2024 Jan; 64(1):124-131. PubMed ID: 38069526
[TBL] [Abstract][Full Text] [Related]
27. The impact of a regular erythrocytapheresis programme on the acute and chronic complications of sickle cell disease in adults.
Kalff A; Dowsing C; Grigg A
Br J Haematol; 2010 Jun; 149(5):768-74. PubMed ID: 20346014
[TBL] [Abstract][Full Text] [Related]
28. Indications for transfusion in the management of sickle cell disease.
Han H; Hensch L; Tubman VN
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):696-703. PubMed ID: 34889416
[TBL] [Abstract][Full Text] [Related]
29. Transfusion support for patients with sickle cell disease.
Wallace LR; Thibodeaux SR
Transfus Apher Sci; 2022 Oct; 61(5):103556. PubMed ID: 36100552
[TBL] [Abstract][Full Text] [Related]
30. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease.
Kim HC; Dugan NP; Silber JH; Martin MB; Schwartz E; Ohene-Frempong K; Cohen AR
Blood; 1994 Feb; 83(4):1136-42. PubMed ID: 8111053
[TBL] [Abstract][Full Text] [Related]
31. Effects of repleting organic phosphates in banked erythrocytes on plasma metabolites and vasoactive mediators after red cell exchange transfusion in sickle cell disease.
Lopez Domowicz DA; Welsby I; Esther CR; Zhu H; Marek RD; Lee G; Shah N; Poisson JL; McMahon TJ
Blood Transfus; 2020 May; 18(3):200-207. PubMed ID: 32203007
[TBL] [Abstract][Full Text] [Related]
32. Effects of red blood cell (RBC) transfusion on sickle cell disease recipient plasma and RBC metabolism.
Culp-Hill R; Srinivasan AJ; Gehrke S; Kamyszek R; Ansari A; Shah N; Welsby I; D'Alessandro A
Transfusion; 2018 Dec; 58(12):2797-2806. PubMed ID: 30265764
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion.
Uhlmann EJ; Shenoy S; Goodnough LT
Transfusion; 2014 Feb; 54(2):384-8. PubMed ID: 23692505
[TBL] [Abstract][Full Text] [Related]
34. Red cell exchange in sickle cell disease.
Swerdlow PS
Hematology Am Soc Hematol Educ Program; 2006; ():48-53. PubMed ID: 17124039
[TBL] [Abstract][Full Text] [Related]
35. Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease.
Kelly S
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):646-652. PubMed ID: 38066846
[TBL] [Abstract][Full Text] [Related]
36. Transfusion Therapy in Children With Sickle Cell Disease.
Inati A; Mansour AG; Sabbouh T; Amhez G; Hachem A; Abbas HA
J Pediatr Hematol Oncol; 2017 Mar; 39(2):126-132. PubMed ID: 27509379
[TBL] [Abstract][Full Text] [Related]
37. Indications for red cell transfusion in sickle cell disease.
Ohene-Frempong K
Semin Hematol; 2001 Jan; 38(1 Suppl 1):5-13. PubMed ID: 11206961
[TBL] [Abstract][Full Text] [Related]
38. Erythrocytapheresis for chronic transfusion therapy in sickle cell disease: survey of current practices and review of the literature.
Kelly S; Quirolo K; Marsh A; Neumayr L; Garcia A; Custer B
Transfusion; 2016 Nov; 56(11):2877-2888. PubMed ID: 27759170
[TBL] [Abstract][Full Text] [Related]
39. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
[TBL] [Abstract][Full Text] [Related]
40. Iron overload in adults with sickle cell disease who have received intermittent red blood cell transfusions.
Pack-Mabien A; Brown B; Herbert DE; Haynes J
J Am Assoc Nurse Pract; 2015 Oct; 27(10):591-6. PubMed ID: 25711464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
